Stifel initiated coverage on Kura Oncology with a new price target
$KURA
Biotechnology: Pharmaceutical Preparations
Health Care
Stifel initiated coverage of Kura Oncology with a rating of Buy and set a new price target of $25.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/4/2025 | Neutral | Guggenheim | |
| 2/6/2025 | Buy → Neutral | BTIG Research | |
| 10/24/2024 | $27.00 | Buy | UBS |
| 10/14/2024 | $26.00 → $19.00 | Buy → Hold | Stifel |
| 12/22/2023 | $26.00 | Buy | Mizuho |
| 8/11/2023 | $31.00 | Buy | BofA Securities |
| 7/27/2023 | $10.50 | Sector Perform | Scotiabank |
| 5/17/2023 | $31.00 | Buy | BTIG Research |
Guggenheim initiated coverage of Kura Oncology with a rating of Neutral
BTIG Research downgraded Kura Oncology from Buy to Neutral
UBS initiated coverage of Kura Oncology with a rating of Buy and set a new price target of $27.00
– KOMET-017-IC trial of intensive chemotherapy combination will assess MRD negative CR and EFS as dual-primary endpoints to support potential U.S. accelerated and full approval – – KOMET-017-NIC trial of venetoclax / azacitidine combination will assess CR and OS as dual-primary endpoints to support potential U.S. accelerated and full approval – SAN DIEGO and TOKYO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") today announced that the first patient has been dosed under the KOMET-017 clinical trial protocol (NCT07007312), comprising two independent, global, randomized double-blind, placebo-controlled Phase 3 tria
– KOMET-001 in R/R NPM1-m AML met its primary endpoint with ziftomenib monotherapy demonstrating significant clinical benefit and deep responses – – Consistent activity across pre-specified subgroups, regardless of prior HSCT, prior venetoclax, lines of therapy, or FLT3/IDH co-mutations – – Favorable safety and tolerability profile, including a lack of clinically significant QTc prolongation or myelosuppression – – Prescription Drug User Fee Act (PDUFA) target action date for FDA Priority Review of ziftomenib in adults with R/R NPM1-m AML set for November 30, 2025 – SAN DIEGO and TOKYO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA) and Kyowa Kirin Co., Ltd. (TSE
SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in the following investor conference. UBS Virtual Oncology DayWednesday, October 1, 20252:30 p.m. ET / 11:30 a.m. PT A live audio webcast will be available in the Investors section of Kura's website at https://kuraoncology.com/, with an archived replay available following the event. About Kura Oncology Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines f
4 - Kura Oncology, Inc. (0001422143) (Issuer)
10-Q - Kura Oncology, Inc. (0001422143) (Filer)
8-K - Kura Oncology, Inc. (0001422143) (Filer)
8-K - Kura Oncology, Inc. (0001422143) (Filer)
4 - Kura Oncology, Inc. (0001422143) (Issuer)
4 - Kura Oncology, Inc. (0001422143) (Issuer)
4 - Kura Oncology, Inc. (0001422143) (Issuer)
– FDA Priority Review of New Drug Application (NDA) for ziftomenib in adults with R/R NPM1-m AML with Prescription Drug User Fee Act (PDUFA) target action date set for November 30, 2025 – – Fully engaged in commercial readiness activities in alignment with regulatory review timeline – – KOMET-017-IC (intensive chemotherapy) and NIC (non-intensive chemotherapy) phase 3 studies in newly diagnosed AML on track to start in 2H 2025 – – Three clinical abstracts from Kura's farnesyl transferase inhibitors (FTI) development program accepted for presentation at the 2025 ESMO Congress – – $630.7 million in pro forma cash, together with anticipated collaboration agreement payments, expected to supp
SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report second quarter 2025 financial results after the close of U.S. financial markets on Thursday, August 7, 2025. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (800) 579-2543 for domestic callers and (785) 424-1789 for international callers and entering the conference ID: KURAQ2. A live webcast and archived rep
– NDA submitted in 1Q 2025 for ziftomenib for the treatment of adult patients with relapsed or refractory AML with an NPM1 mutation – – Data from Phase 1b/2 registration-directed trial of ziftomenib selected for oral presentation at ASCO Annual Meeting – – $45.0 million milestone payment earned for NDA submission under collaboration agreement with Kyowa Kirin – – First patients dosed in Phase 1 trial of ziftomenib plus imatinib in GIST – – $703.2 million in pro forma cash, together with anticipated collaboration agreement payments, expected to support ziftomenib commercialization through the frontline AML combination setting – – Management to host webcast and conference call today at 4:
SC 13G - Kura Oncology, Inc. (0001422143) (Subject)
SC 13G/A - Kura Oncology, Inc. (0001422143) (Subject)
SC 13G/A - Kura Oncology, Inc. (0001422143) (Subject)
PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass' or ‘the Company'), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee. Carol has more than 25 years of experience in investment banking, equity capital markets, corporate finance and business development in the healthcare sector. She currently serves on the Board of Directors for Insmed Incorporated (NAS
– Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry
SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Michael Vasconcelles, M.D., to its Board of Directors. Dr. Vasconcelles is an accomplished biopharmaceutical executive with more than 25 years of oncology drug development experience and industry leadership. "On behalf of our Board and leadership team, we are delighted to have Mike join our Board of Directors," said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. "His extensive experience in R&D and regulatory aff